MAGP-2: An Extracellular Factor Shown to Have Pro-Angiogenic Properties in vivo

Tech ID:  06-05


Background
Excessive angiogenesis has emerged as an essential feature of tumor development and appears to be regulated in part by extracellular matrix proteins. Scientists at National Jewish Health have identified an extracellular matrix protein (designated MAGP-2) that acts as a pro-angiogenic agent in vivo.
 
Potential Applications
  • A target for inhibiting angiogenesis in cancer and other angiogenesis-dependent diseases
  • Stimulating neovascularization by administration of MAGP-2 to ischemic tissues in coronary artery disease, stroke, and delayed wound healing
  • A diagnostic biomarker, especially for cancer
 
Advantages of Invention
Because of its extracellular nature, MAGP-2 can be easily detectable and targetable by antibody-based technologies for example.
 
State of Development
Our scientists have shown the following:
In vitro:
MAGP-2 is over expressed in human uterine tumor samples
Endothelial cell expression of MAGP-2 increases during angiogenesis in vitro
MAGP-2 stimulates angiogenic sprouting in 3-dimensional collagen cultures
MAGP-2 increases endothelial cell proliferation and invasion in vitro
In vivo:
Significant enhancement of neovascularization when MAGP-2 was implanted into mice through matrigel plugs
MAGP-2 increases tumor size and angiogenesis in mice
 
Publications
•  Albig, Allan R., Thessa G. Roy, Darryl J. Becenti, and William P. Schiemann. "Transcriptome Analysis of Endothelial Cell Gene Expression Induced by Growth on Matrigel Matrices: Identification and Characterization of MAGP-2 and Lumican as Novel Regulators of Angiogenesis." Angiogenesis 10.3 (2007): 197-216. Print. PMID: 17632767.
•  Albig, Allan R., Darryl J. Becenti, Thessa G. Roy, and William P. Schiemann. "Microfibril-associate Glycoprotein-2 (MAGP-2) Promotes Angiogenic Cell Sprouting by Blocking Notch Signaling in Endothelial Cells." Microvascular Research 76.1 (2008): 7-14. Print. PMID: 18417156.

Inventors
William P. Schiemann, PhD and Allan Albig, PhD

Patent Status
U.S. Patents #8,158,107 and #8,629,107. Other U.S. Patents Pending.

Licensing Status
This technology is available for licensing.

For Further Information, Contact:
Emmanuel Hilaire, PhD
Manager
Technology Transfer Office
National Jewish Health
1400 Jackson Street, Room M206b
Denver, CO 80206
Voice: 303.398.1262
Fax: 303.270.2352
HilaireE@njhealth.org
Bookmark and Share

Faculty by Research

The discoveries made in the laboratories at National Jewish Health have a profound impact on the understanding and treatment of human disease.

Browse our Faculty by Area of Research.